Cargando…
(177)Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment
BACKGROUND: Metastatic bone lesion is a common syndrome of many cancer diseases in an advanced state. The major symptom is severe pain, spinal cord compression, and pathological fracture, associated with an obvious morbidity. Common treatments including systemic application of bisphosphonate drugs a...
Autores principales: | Bergmann, Ralf, Meckel, Marian, Kubíček, Vojtěch, Pietzsch, Jens, Steinbach, Jörg, Hermann, Petr, Rösch, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715021/ https://www.ncbi.nlm.nih.gov/pubmed/26780082 http://dx.doi.org/10.1186/s13550-016-0161-3 |
Ejemplares similares
-
Preclinical Characterization of the (177)Lu-Labeled Prostate Stem Cell Antigen (PSCA)-Specific Monoclonal Antibody 7F5
por: Striese, Franziska, et al.
Publicado: (2023) -
Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases
por: Fernández, René, et al.
Publicado: (2021) -
[(177)Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results
por: Yadav, Madhav Prasad, et al.
Publicado: (2020) -
Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021) -
Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases
por: Pfannkuchen, Nina, et al.
Publicado: (2017)